

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO Box 1450 Alexasofan, Virginia 22313-1450 www.repto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/698,858	10/31/2003	Gary T. Seim	GUID.014US01	9341
	7590 02/22/201 ORTH & FUNK	EXAMINER		
8500 Normandale Lake Blvd			HOLMES, REX R	
SUITE 320 MINNEAPOLI	IS. MN 55437	ART UNIT	PAPER NUMBER	
	,		3762	
			MAIL DATE	DELIVERY MODE
			02/22/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Ī	Application No.	Applicant(s)		
	10/698,858	SEIM ET AL.		
	Examiner	Art Unit		
	REX HOLMES	3762		

	REX HOLMES	3762				
The MAILING DATE of this communication appe	ars on the cover sheet with the o	orrespondence add	ress			
THE REPLY FILED 03 February 2010 FAILS TO PLACE THIS	APPLICATION IN CONDITION FO	R ALLOWANCE.				
 M The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following in application in condition for allowance; (2) a Notice of Appe for Continued Examination (RCE) in compliance with 37 C periods: 	the same day as filing a Notice of a eplies: (1) an amendment, affidavi al (with appeal fee) in compliance	Appeal. To avoid abar t, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request			
a) The period for reply expires months from the mailing	date of the final rejection.					
b) The period for reply expires on: (1) the mailing date of this Ar no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (I MONTHS OF THE FINAL REJECTION. See MPEP 706.07(I	ter than SIX MONTHS from the mailing	date of the final rejection	n.			
Extensions of time may be obtained under 37 CFR 1,136(a). The date have been filled is the date for purposes of determining the period of exhaunder 37 CFR 1,17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any pely received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1,704(b). NOTICE OF APPEAL.	ension and the corresponding amount of hortened statutory period for reply origi	of the fee. The appropria nally set in the final Office	ate extension fee e action; or (2) as			
 The Notice of Appeal was filed on A brief in compl filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi 	sion thereof (37 CFR 41.37(e)), to	avoid dismissal of the				
AMENDMENTS						
 The proposed amendment(s) filed after a final rejection, to (a) They raise new issues that would require further corn (b) They raise the issue of new matter (see NOTE below (c) They are not deemed to place the application in bett appeal; and/or (d) They present additional claims without canceling a company of the present additional claims. 	sideration and/or search (see NOT w); er form for appeal by materially rec	E below); ducing or simplifying the				
NOTE: (See 37 CFR 1.116 and 41.33(a)).						
 The amendments are not in compliance with 37 CFR 1.12 		mpliant Amendment (I	PTOL-324).			
 Applicant's reply has overcome the following rejection(s): 						
 Newly proposed or amended claim(s) would be all non-allowable claim(s). 		•				
7. Mero purposes of appeal, the proposed amendment(s), a) [I how the new or amended claims would be rejected is proved the status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: 1,4,6,13-15,18,20,21,29,30,33,36,39-41	ided below or appended.	be entered and an e	planation of			
Claim(s) withdrawn from consideration:						
AFFIDAVIT OR OTHER EVIDENCE						
 The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e). 						
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to or showing a good and sufficient reasons why it is necessary 	vercome <u>all</u> rejections under appea	l and/or appellant fail:	to provide a			
 The affidavit or other evidence is entered. An explanation 	of the status of the claims after er	ntry is below or attach	ed.			
REQUEST FOR RECONSIDERATION/OTHER						
11. \(\times \) The request for reconsideration has been considered but See Continuation Sheet.	·	condition for allowan	ce because:			
12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s).						
 Other: The broadening of claim 64 by removing comprise reasoning provided in the frinal office action dated 12/8/09. 	s does not change the rejection ar	nd the claim is still reje	cted under the			
	/George R Evanisko/					

/George R Evanisko/ Primary Examiner, Art Unit 3762

Application No.

Continuation of 11. does NOT place the application in condition for allowance because: The Applicants argue that Klepfer in view of Levine fails to disclose disabling ATP therapy and delivering non atrial tracking therapy. As pointed out by the Applicant Klepfer discloses in Paragraph 85 that the stimulation therapy can be adjusted and then can be restarted after the adjustment. Klepfer further discloses that one of the many therapies available in the system are non-atrial tracking pacing therapies such as VVI and DDI therapies (e.g. 59, Claims 12 and 22). It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the therapy that the system switches to after ATP therapy as taught by Klepfer e.g. 85, with one of the other therapies as disclosed by Klepfer that does not require an atrial sensing lead, since such a modification would provide the predictable results of switching the therapy from one that requires an atrial lead to another therapy that does not require an atrial lead for providing stimulation to the heart after the device withholds ATP therapy due to atrial lead failure. The Applicant further argues that Klepfer may teach changing therapies but the language of the specification states that the therapy is restarted and therefore the previous therapy is restarted and not the changed therapy. The Examiner respectfully disagrees. The language of paragraph 85 states that the therapy is adjusted and once adjusted the therapy may be restarted, as in the newly adjusted therapy. There would be no need to adjust the therapy if the process just reused the previous therapy. The Applicant next argues that Klepfer fails to determine a lead related condition as the lead related conditions listed in paragraph 111 do not utilize the procedure of paragraph 85. It is noted that step 485 as disclosed in paragraph 85 which clearly states that additional diagnostic procedures known in the art are performed in step 485 after detecting the abnormal beat, such as, ... diagnosing a lead-related problem. It is noted that Paragraph 111 was used to show the types of known lead-related problems and procedures for detecting problems that are known in the art. Therefore the teachings of Klepfer in view of Levine show and teach each and every element of the claim. Regarding claim 20, the claim states that the disabling ATP therapy deliver in response to any of the... Thus, the claim only requires one of the cases to be true to disable, not all of the cases. Therefore, based on the arguments above and the rejections dated 2/3/10, the claim is properly rejected.